In particular, the tested mutations mostly decreased the accessibility of a large number of enhancers and superenhancers, many of which were specific to either pro-B cells, T cells, macrophages, bone marrow tissue, or thymus, which could explain why SMARCA4 mutations are ubiquitous across different cancer types while promoting cell type-specific oncogenesis. Here, SMARCA4 is linked to cancer.